CO4850588A1 - Compuestos para inmunoterapia del cancer de prostata . - Google Patents

Compuestos para inmunoterapia del cancer de prostata .

Info

Publication number
CO4850588A1
CO4850588A1 CO98010249A CO98010249A CO4850588A1 CO 4850588 A1 CO4850588 A1 CO 4850588A1 CO 98010249 A CO98010249 A CO 98010249A CO 98010249 A CO98010249 A CO 98010249A CO 4850588 A1 CO4850588 A1 CO 4850588A1
Authority
CO
Colombia
Prior art keywords
chains
polypeptide
chain
nucleotide
protein
Prior art date
Application number
CO98010249A
Other languages
English (en)
Inventor
Jiangchun Xu
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of CO4850588A1 publication Critical patent/CO4850588A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un polipéptido que comprende la porción inmunogénica de unaproteína de prostata, o una variante de la misma, en donde dicha proteína comprende una cadena de aminoácido, codificada por una molécula de DNA que tiene una cadena seleccionada entre el grupo que consiste de las cadenas de nucleótidos que se enumeran en las SEQ ID Nos. 2, 3, 8, 29, 41-45, 47, 52, 54-65, 7O, 73-74, 79, 81, 87, 90, 92, 93, 97, 103, 104, 107, 109-111, 115-160, 171, 173, 175 y 177, los complementos de dichas cadenas de nucleótidos y las variantes de las mismas cadenas. Una molécula de DNA que comprende una cadena de nucleótidos que codifica el polipéptido de la reivindicación 1. 1Un compuesto farmacológico para el tratamiento del cáncer de próstata, que comprende un polipéptido y un portador que no presente rechazo fisiológico, donde el polipéptido comprende una porción inmunogénica de una proteína de próstata o de una variante de la misma, donde dicha proteína comprende una cadena de aminoácido codificada por una molécula de DNA que tiene una cadena seleccionada entre el grupo que consiste de las cadenas de nucleótidos que se enumeran en las SEQ ID Nos: 5-7, 30, 40, 46, 53, 66-69, 71, 72, 75,-78, 80, 82-86, 88, 89,91, 94-96, 98-102, 105, 106 y 161-170, los complementos de dichas cadenas de nucleótidos y las variantes de las mismas cadenas. 1Una vacuna para el tratamiento del cáncer de próstata, que comprende un polipéptido y un acrecentador no específico de la respuesta inmunológica, donde dicho polipéptido comprende una porción inmunogénica de una proteína de próstata o una variante de la misma, donde dicha proteína comprende una cadena de aminoácido codificada por una molécula de DNA que tiene una cadena seleccionada entre el grupo que consiste de las cadenas de nucleótidos que se enumeran en las SEQ ID Nos: 5-7, 30, 40, 46, 53, 66-69, 71, 72, 75, 78, 80, 82-86, 88, 89, 91, 94-96, 98-102, 105, 106 y 161-170, los complementos de dichas cadenas de nucleótidos y las variantes de las mismas cadenas.
CO98010249A 1997-02-25 1998-02-25 Compuestos para inmunoterapia del cancer de prostata . CO4850588A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80609997A 1997-02-25 1997-02-25
US90480497A 1997-08-01 1997-08-01
US09/020,956 US6261562B1 (en) 1997-02-25 1998-02-09 Compounds for immunotherapy of prostate cancer and methods for their use

Publications (1)

Publication Number Publication Date
CO4850588A1 true CO4850588A1 (es) 1999-10-26

Family

ID=27122845

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98010249A CO4850588A1 (es) 1997-02-25 1998-02-25 Compuestos para inmunoterapia del cancer de prostata .

Country Status (8)

Country Link
US (1) US6261562B1 (es)
EP (2) EP2298877B1 (es)
KR (1) KR100572817B1 (es)
AR (2) AR008727A1 (es)
CA (1) CA2742641A1 (es)
CO (1) CO4850588A1 (es)
SA (1) SA98190265B1 (es)
TW (1) TW581808B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6657056B2 (en) * 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO1998045420A1 (en) 1997-04-10 1998-10-15 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US20020106688A1 (en) * 1997-08-05 2002-08-08 Moncef Jenboubi Identification of gene sequences and gene products and their specific function and relationship to pathologies in a mammal
US6623923B1 (en) * 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US7063959B1 (en) * 1998-12-30 2006-06-20 Beth Israel Deaconess Medical Center, Inc. Compositions of the SOC/CRAC calcium channel protein family
WO2000071711A2 (en) * 1999-05-20 2000-11-30 Fahri Saatcioglu Differentially expressed genes in prostate cancer
PT1222266E (pt) * 1999-09-29 2006-07-31 Diagnocure Inc Arn mensageiro de pca3 em tecidos benignos e malignos da prostata
US7611892B2 (en) * 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US8565860B2 (en) 2000-08-21 2013-10-22 Biosensors International Group, Ltd. Radioactive emission detector equipped with a position tracking system
US7652259B2 (en) * 2000-08-21 2010-01-26 Spectrum Dynamics Llc Apparatus and methods for imaging and attenuation correction
US8489176B1 (en) 2000-08-21 2013-07-16 Spectrum Dynamics Llc Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
WO2005119025A2 (en) 2004-06-01 2005-12-15 Spectrum Dynamics Llc Radioactive-emission-measurement optimization to specific body structures
US8036731B2 (en) 2001-01-22 2011-10-11 Spectrum Dynamics Llc Ingestible pill for diagnosing a gastrointestinal tract
US8909325B2 (en) 2000-08-21 2014-12-09 Biosensors International Group, Ltd. Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
US20020123081A1 (en) * 2000-09-28 2002-09-05 Jennifer Richardson Methods of use of alpha-methylacyl-CoA racemase in hormone refractory and metastatic prostate cancers
US7048931B1 (en) * 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
IL157007A0 (en) 2001-01-22 2004-02-08 Target Technologies Ltd V Ingestible device
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6897024B2 (en) * 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US20040116807A1 (en) * 2002-10-17 2004-06-17 Roni Amrami Blood vessels wall imaging catheter
EP1592809B1 (en) 2003-02-07 2013-04-10 Diagnocure Inc. Method to detect prostate cancer in a sample
KR20060073589A (ko) * 2003-08-07 2006-06-28 카이론 코포레이션 항암 치료법을 위한 표적으로서 트레포일 인자 3(ｔｆｆ3)
CN1981210A (zh) 2004-01-13 2007-06-13 光谱动力学有限责任公司 多维图像重构
WO2008010227A2 (en) 2006-07-19 2008-01-24 Spectrum Dynamics Llc Imaging protocols
WO2006075333A2 (en) 2005-01-13 2006-07-20 Spectrum Dynamics Llc Multi-dimensional image reconstruction and analysis for expert-system diagnosis
WO2006051531A2 (en) 2004-11-09 2006-05-18 Spectrum Dynamics Llc Radioimaging
US7968851B2 (en) 2004-01-13 2011-06-28 Spectrum Dynamics Llc Dynamic spect camera
US9470801B2 (en) 2004-01-13 2016-10-18 Spectrum Dynamics Llc Gating with anatomically varying durations
WO2007010537A2 (en) 2005-07-19 2007-01-25 Spectrum Dynamics Llc Reconstruction stabilizer and active vision
US8586932B2 (en) 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
US8571881B2 (en) 2004-11-09 2013-10-29 Spectrum Dynamics, Llc Radiopharmaceutical dispensing, administration, and imaging
EP1766550A2 (en) 2004-06-01 2007-03-28 Spectrum Dynamics LLC Methods of view selection for radioactive emission measurements
US9316743B2 (en) 2004-11-09 2016-04-19 Biosensors International Group, Ltd. System and method for radioactive emission measurement
US9943274B2 (en) 2004-11-09 2018-04-17 Spectrum Dynamics Medical Limited Radioimaging using low dose isotope
US8000773B2 (en) 2004-11-09 2011-08-16 Spectrum Dynamics Llc Radioimaging
US8615405B2 (en) 2004-11-09 2013-12-24 Biosensors International Group, Ltd. Imaging system customization using data from radiopharmaceutical-associated data carrier
EP1824520B1 (en) * 2004-11-17 2016-04-27 Biosensors International Group, Ltd. Methods of detecting prostate cancer
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US8837793B2 (en) 2005-07-19 2014-09-16 Biosensors International Group, Ltd. Reconstruction stabilizer and active vision
US8644910B2 (en) 2005-07-19 2014-02-04 Biosensors International Group, Ltd. Imaging protocols
EP1952180B1 (en) * 2005-11-09 2017-01-04 Biosensors International Group, Ltd. Dynamic spect camera
EP1966984A2 (en) 2005-12-28 2008-09-10 Starhome GmbH Optimal voicemail deposit for roaming cellular telephony
US8894974B2 (en) 2006-05-11 2014-11-25 Spectrum Dynamics Llc Radiopharmaceuticals for diagnosis and therapy
US8610075B2 (en) 2006-11-13 2013-12-17 Biosensors International Group Ltd. Radioimaging applications of and novel formulations of teboroxime
WO2008075362A2 (en) 2006-12-20 2008-06-26 Spectrum Dynamics Llc A method, a system, and an apparatus for using and processing multidimensional data
US8521253B2 (en) 2007-10-29 2013-08-27 Spectrum Dynamics Llc Prostate imaging
JP2012526544A (ja) * 2009-05-12 2012-11-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７
US8338788B2 (en) 2009-07-29 2012-12-25 Spectrum Dynamics Llc Method and system of optimized volumetric imaging
RU2461916C1 (ru) * 2011-01-12 2012-09-20 Государственное образовательное учреждение высшего профессионального образования Томский государственный университет систем управления и радиоэлектроники (ТУСУР) Полупроводниковый светоизлучающий прибор

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2095698A (en) 1937-10-12 Ox yoke model
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4673562A (en) 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4735792A (en) 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5041289A (en) 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
EP1026253B2 (en) 1989-03-21 2012-12-19 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
DE69126620T2 (de) 1990-10-18 1997-10-02 Cellpro Inc Vorrichtung und verfahren zur trennung von partikeln mittels eines biegsamen gefässes
US5851764A (en) 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
WO1993014753A1 (en) 1992-01-27 1993-08-05 The Board Of Trustees Of The Leland Stanford Junior University Histamine derivatives and methods for their use
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
JP4204642B2 (ja) 1992-11-05 2009-01-07 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 前立腺に特異的な膜抗原
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
JPH09504000A (ja) 1993-08-11 1997-04-22 ジェナー テクノロジーズ 前立腺癌ワクチン
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
CA2189774A1 (en) 1994-05-10 1995-11-16 Donald J. Tindall Recombinant hk2 polypeptide
WO1997033909A2 (en) 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
CA2269755A1 (en) 1996-10-25 1998-04-30 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AU5923398A (en) 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Polynucleotides and polypeptides encoding receptors
CA2281952C (en) 1997-02-25 2011-07-19 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
DE69831222T2 (de) 1997-02-25 2006-07-13 Corixa Corp., Seattle Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
US6020478A (en) 1997-02-28 2000-02-01 Incyte Pharmaceuticals, Inc. Human tumor-associated antigen
CA2284131A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
EP0973898A2 (en) 1997-04-10 2000-01-26 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
AU8555198A (en) 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in prostate
AU8554798A (en) 1997-08-01 1999-02-22 Genset 5'ests for non tissue specific secreted proteins
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
CA2302644A1 (en) 1997-11-13 1999-05-27 Genset S.A. Extended cdnas for secreted proteins
ATE440951T1 (de) 1997-12-17 2009-09-15 Serono Genetics Inst Sa Verlängerte cdns, die für sekretierte proteine kodieren
DE19805633A1 (de) 1998-02-12 1999-08-19 Basf Ag Neue Serinprotease aus der Prostata

Also Published As

Publication number Publication date
EP2298877A1 (en) 2011-03-23
EP2143731A1 (en) 2010-01-13
TW581808B (en) 2004-04-01
SA98190265B1 (ar) 2006-11-12
KR20000075699A (ko) 2000-12-26
CA2742641A1 (en) 1998-08-27
KR100572817B1 (ko) 2006-04-24
AR062300A2 (es) 2008-10-29
AR008727A1 (es) 2000-02-09
EP2298877B1 (en) 2014-09-24
US6261562B1 (en) 2001-07-17

Similar Documents

Publication Publication Date Title
CO4850588A1 (es) Compuestos para inmunoterapia del cancer de prostata .
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
DK289688A (da) Ekspression af proapolipoprotein a-i.
AR012035A1 (es) Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico
ATE114651T1 (de) Alkynylamino-nukleotide.
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
AR038568A1 (es) Anticuerpos anti-a beta y su uso
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DK296189A (da) Nucleinsyresekvenser, som koder for peptidsekvenser af carcinoembryonisk antigen-familien
ATE196926T1 (de) Gen grb3-3, variante und ihre verwendungen
BRPI0308119A2 (pt) microorganismo como portadores de seqüências de nucleotídeos codificando para antígenos de células para o tratamento de tumores.
DK1108786T3 (da) Hidtil ukendt kollektin
DK38889D0 (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
ES2123641T3 (es) Secuencias de acidos nucleicos que codifican o que son complementarias a secuencias de acidos nucleicos que codifican para el receptor de la interleucina 9.
ATE230026T1 (de) Menschliches wachstumsgen und minderwuchse gen bereich
DK1127064T3 (da) Hidtil ukendte aminosyresekvenser, DNA, der koder for aminosyresekvenserme, antistoffer, der er rettet mod sådanne sekvenser, og forskellige anvendelser deraf
DK1117682T3 (da) Chi-conotoksin-peptider som inhibitorer af neuronale amintransportere
CO5280140A1 (es) Antigeno (c42) asociado a tumores
PE20000759A1 (es) Gen de la citocroma oxidasa de hidroquinona del tipo bd
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
DE69828902D1 (de) Polypeptide mit 5-aminolevulinsäure synthaseaktivität und deren nukleinsäuren
ES2176514T3 (es) Uso de derivados de perfluoroalquilo de aminoacidos como inhibidores de metalo-beta-lactamasa.
ES2271040T3 (es) Factores especificos de hifa procedentes de candida albicans.
ATE317900T1 (de) Für hm1.24 antigen kodierendes gen und dessen promotor